CA2588909A1 - Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof - Google Patents

Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof Download PDF

Info

Publication number
CA2588909A1
CA2588909A1 CA002588909A CA2588909A CA2588909A1 CA 2588909 A1 CA2588909 A1 CA 2588909A1 CA 002588909 A CA002588909 A CA 002588909A CA 2588909 A CA2588909 A CA 2588909A CA 2588909 A1 CA2588909 A1 CA 2588909A1
Authority
CA
Canada
Prior art keywords
alkyl
indazol
dihydro
chromen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002588909A
Other languages
English (en)
French (fr)
Inventor
Arthur R. Gomtsyan
Erol K. Bayburt
Robert G. Schmidt, Jr.
Chih-Hung Lee
S. Brian Brown
K. Tammie Jinkerson
R. John Koenig
F. Jerome Daanen
Steve Latshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2588909A1 publication Critical patent/CA2588909A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002588909A 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof Abandoned CA2588909A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63063604P 2004-11-24 2004-11-24
US60/630,636 2004-11-24
PCT/US2005/042545 WO2006065484A2 (en) 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Publications (1)

Publication Number Publication Date
CA2588909A1 true CA2588909A1 (en) 2006-06-22

Family

ID=36588346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002588909A Abandoned CA2588909A1 (en) 2004-11-24 2005-11-22 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof

Country Status (13)

Country Link
US (2) US7812019B2 (enExample)
EP (2) EP2527339A1 (enExample)
JP (2) JP4932730B2 (enExample)
KR (2) KR20120137420A (enExample)
CN (2) CN101443327A (enExample)
AU (1) AU2005316972B2 (enExample)
BR (1) BRPI0518581A2 (enExample)
CA (1) CA2588909A1 (enExample)
IL (1) IL183321A0 (enExample)
MX (1) MX2007006205A (enExample)
NZ (1) NZ555318A (enExample)
TW (1) TW200633712A (enExample)
WO (1) WO2006065484A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005086331A2 (en) * 2004-03-02 2005-09-15 Rosemount, Inc. Process device with improved power generation
US8538560B2 (en) 2004-04-29 2013-09-17 Rosemount Inc. Wireless power and communication unit for process field devices
US8145180B2 (en) * 2004-05-21 2012-03-27 Rosemount Inc. Power generation for process devices
JP4932730B2 (ja) * 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ1(vr1)受容体を阻害するクロマニル尿素化合物およびその使用
US20060160850A1 (en) * 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
EP1957464A1 (en) * 2005-10-28 2008-08-20 Abbott Laboratories INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
MY144307A (en) * 2006-04-18 2011-08-29 Abbott Lab Antagonists of the vanilloid receptor subtype 1 (vr1) and uses thereof
US7913566B2 (en) 2006-05-23 2011-03-29 Rosemount Inc. Industrial process device utilizing magnetic induction
WO2008059339A2 (en) * 2006-11-13 2008-05-22 Glenmark Pharmaceuticals S.A. Isoquinoline derivatives as vanilloid receptor modulators
US8030504B2 (en) * 2006-12-20 2011-10-04 Abbott Laboratories Antagonists of the TRPV1 receptor and uses thereof
WO2008110863A1 (en) * 2007-03-15 2008-09-18 Glenmark Pharmaceuticals S.A. Indazole derivatives and their use as vanilloid receptor ligands
CL2008003749A1 (es) 2007-12-17 2010-01-15 Janssen Pharmaceutica Nv Compuestos derivados de imidazol, oxazol, y tiazol pirimidina, moduladores de trpv1, proceso de preparacion, composicion farmaceutica y su uso en el tratamiento de enfermedades, trastornos o condicion de dolor, prurito, artritis, tos, asma, trastorno del oido interno y enfermedad inflamatoria intestinal, entre otras.
WO2009095726A1 (en) * 2008-01-29 2009-08-06 Glenmark Pharmaceuticals, S.A. Acrylamide derivatives as vanilloid receptor 1 modulators
JP5305704B2 (ja) * 2008-03-24 2013-10-02 富士フイルム株式会社 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版
US8250924B2 (en) 2008-04-22 2012-08-28 Rosemount Inc. Industrial process device utilizing piezoelectric transducer
US8694060B2 (en) 2008-06-17 2014-04-08 Rosemount Inc. Form factor and electromagnetic interference protection for process device wireless adapters
CA2726707C (en) 2008-06-17 2016-01-19 Rosemount Inc. Rf adapter for field device with low voltage intrinsic safety clamping
JP5255698B2 (ja) * 2008-06-17 2013-08-07 ローズマウント インコーポレイテッド 電圧降下が可変のフィールド機器用無線アダプタ
US8929948B2 (en) 2008-06-17 2015-01-06 Rosemount Inc. Wireless communication adapter for field devices
WO2010023512A1 (en) * 2008-08-28 2010-03-04 Matrix Laboratories Ltd. Novel vanilloid receptor modulators, process for their preparation and pharmaceutical compositions containing them
MX2011004090A (es) * 2008-10-17 2011-05-31 Abbott Lab Antagonistas trpv1.
JP2012505907A (ja) * 2008-10-17 2012-03-08 アボット・ラボラトリーズ Trpv1拮抗薬
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN101654435B (zh) * 2009-06-09 2014-01-29 沈阳药科大学 N-苯甲基喹啉羧酸类化合物、组合物及其制备方法
US20100318007A1 (en) * 2009-06-10 2010-12-16 O'brien Donald J Electromechanical tactile stimulation devices and methods
US9674976B2 (en) 2009-06-16 2017-06-06 Rosemount Inc. Wireless process communication adapter with improved encapsulation
US8626087B2 (en) 2009-06-16 2014-01-07 Rosemount Inc. Wire harness for field devices used in a hazardous locations
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5,6元杂芳双环化合物作为激酶抑制剂
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
US10761524B2 (en) 2010-08-12 2020-09-01 Rosemount Inc. Wireless adapter with process diagnostics
UY33966A (es) 2011-03-25 2012-10-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
US9310794B2 (en) 2011-10-27 2016-04-12 Rosemount Inc. Power supply for industrial process field device
US8859584B2 (en) 2011-12-19 2014-10-14 Abbvie, Inc. TRPV1 antagonists
US8969325B2 (en) 2011-12-19 2015-03-03 Abbvie Inc. TRPV1 antagonists
US8796328B2 (en) 2012-06-20 2014-08-05 Abbvie Inc. TRPV1 antagonists
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
US9783527B2 (en) * 2014-09-16 2017-10-10 Abbvie Inc. Indazole ureas and method of use
CN109574972A (zh) * 2018-07-13 2019-04-05 郑州大学 一种3-烷基取代-4-色满酮类化合物及其制备方法
PE20240017A1 (es) * 2020-09-30 2024-01-04 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer
WO2025161263A1 (zh) * 2024-01-31 2025-08-07 深圳晶蛋生物医药科技有限公司 一种苯并吗啉类化合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029668T2 (de) * 1989-03-08 1997-08-07 Merck Sharp & Dohme Tetrahydroquinolin-Derivate, verwendbar bei neurodegenerativen Krankheiten
NL8900565A (nl) 1989-03-08 1990-10-01 Philips Nv Methode voor de verwerking van een radio data signaal, alsmede ontvanger voor de uitvoering van deze methode.
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
CA2264020A1 (en) * 1996-08-26 1998-03-05 Jean Bemis Inhibitors of phospholipase enzymes
CA2389360C (en) 1999-11-16 2008-06-03 Steffen Breitfelder Urea derivatives as anti-inflammatory agents
WO2003097586A1 (en) 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
JP4932730B2 (ja) * 2004-11-24 2012-05-16 アボット・ラボラトリーズ バニロイド受容体サブタイプ1(vr1)受容体を阻害するクロマニル尿素化合物およびその使用
EP1957464A1 (en) * 2005-10-28 2008-08-20 Abbott Laboratories INDAZOLE DERIVATIVES THAT INHIBIT TRPVl RECEPTOR

Also Published As

Publication number Publication date
JP2012111766A (ja) 2012-06-14
NZ555318A (en) 2011-01-28
AU2005316972A1 (en) 2006-06-22
TW200633712A (en) 2006-10-01
US20060128689A1 (en) 2006-06-15
EP2527339A1 (en) 2012-11-28
KR20070086607A (ko) 2007-08-27
AU2005316972B2 (en) 2011-11-10
KR20120137420A (ko) 2012-12-20
CN101443327A (zh) 2009-05-27
CN102161653A (zh) 2011-08-24
JP4932730B2 (ja) 2012-05-16
IL183321A0 (en) 2008-04-13
US7812019B2 (en) 2010-10-12
WO2006065484A2 (en) 2006-06-22
BRPI0518581A2 (pt) 2008-11-25
EP1844038A2 (en) 2007-10-17
KR101250824B1 (ko) 2013-04-05
WO2006065484A3 (en) 2009-02-19
MX2007006205A (es) 2009-02-13
US20110152250A1 (en) 2011-06-23
US8440691B2 (en) 2013-05-14
JP2008532925A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
US8440691B2 (en) Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
US7622493B2 (en) Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof
US7074805B2 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
US20030158188A1 (en) Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US8350083B2 (en) Antagonists of the TRPV1 receptor and uses thereof
CA2590585A1 (en) Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof
EP1836200B1 (en) Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof
HK1169980A (en) Antagonists of the trpv1 receptor and uses thereof
KR20090034787A (ko) 모르피난 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20141015